ライフサイエンスコーパス: FDG-PET

1 FDG-PET detected plaque inflammation in 12/13 patients s

2 FDG-PET revealed high inflammation levels at the site of

3 FDG-PET was performed on a cohort of 79 patients with ne

4 FDG-PET/CT was accurate in diagnosing recurrence in brea

5 ween retinal sensitivity and the MRI and (18)FDG-PET parameters related to brain neurodegeneration.

6 glucose-18 positron emission tomography ((18)FDG-PET).

7 Emission Tomography Computed Tomography (18-FDG PET/CT) scans to assess vascular inflammation (VI) a

8 e demonstrate our method on the GWAS of [18F]FDG-PET measures in the amygdala region using the imagin

9 features extracted from Dixon sequences and FDG PET.

10 lly overlapping) relationship between MR and FDG-PET intensities.

11 eration in AD signature regions from MRI and FDG-PET as surrogates for AD pathophysiology.

12 in predicting residual disease than did any FDG PET/CT interpretation method (42%-46%).

13 ion with high relative metabolic activity at FDG PET had a shorter survival time than did those with

14 e relationship between metabolic activity at FDG PET in the residual lesion identified at brain MR im

15 val time than did those with low activity at FDG PET.

16 Conclusion FDG PET/CT demonstrates high specificity and PPV for det

17 Conclusion FDG PET/CT has satisfactory diagnostic accuracy in the d

18 Conclusion FDG-PET/CT surveillance using Hopkins criteria 12 weeks

19 s, especially by texture features on delayed FDG PET/CT images.

20 vs. 8 +/- 3 mm(2); n = 3 vs. 6), day-4 (18)F-FDG PET (metabolic volume, 87 +/- 23 vs. 118 +/- 14 mm(3

21 defined on diffusion-weighted MRI and (18)F-FDG PET (VOIDWI, VOIPET).

22 igher specificity (0.89 vs. 0.79) than (18)F-FDG PET alone, with no evidence of significant differenc

23 A prespecified (18)F-FDG PET analysis was conducted to assess the predictive

24 in comparison to standard imaging with (18)F-FDG PET and clinical outcome.

25 textural features extracted from both (18)F-FDG PET and CT.

26 complementary information derived from(18)F-FDG PET and diffusion-weighted MRI (DW-MRI) to separate

27 tic marker for NENs in comparison with (18)F-FDG PET and Ki-67 index.

28 Conclusion:(18)F-FDG PET and MR ADC histogram metrics in pediatric DIPG d

29 mages and postgadolinium MR images and (18)F-FDG PET and MR ADC histograms were generated.

30 Baseline brain (18)F-FDG PET and MRI scans were obtained in 33 children from

31 Treatment response by quantitative (18)F-FDG PET assessed by PERCIST 1.0 as early as 9 d into IGF

32 Data about the significance of (18)F-FDG PET at interim assessment and end of treatment in pe

33 h relapsed or refractory MCL underwent (18)F-FDG PET at screening and after 6 cycles of BR therapy.

34 the use of analysis of covariance, all (18)F-FDG PET brain images of MMF patients were compared with

35 Methods:(18)F-FDG PET brain imaging and a comprehensive battery of neu

36 ught to assess the diagnostic value of (18)F-FDG PET combined with MRI (combined (18)F-FDG PET/MRI) i

37 nt study, we aimed to identify RSNs in (18)F-FDG PET data and compare their spatial pattern with thos

38 (18)F-FDG PET data from patients with refractory or advanced d

39 nted independent-component analysis of (18)F-FDG PET data in 5 groups of subjects with cognitive stat

40 Independent-component analysis of (18)F-FDG PET data showed a gradual disruption of functional b

41 (18)F-FDG PET data were acquired along with 2 Dixon MR-AC maps

42 Complete (18)F-FDG PET data were available for 32 of 45 patients.

43 crease costs for clinical trials using (18)F-FDG PET endpoints.

44 Women benefited from a baseline (18)F-FDG PET examination with a 2-min chest-centered dynamic

45 parkinsonism and the promising role of (18)F-FDG PET for assessment and risk stratification of cognit

46 The diagnostic specificity of (18)F-FDG PET for diagnosing multiple-system atrophy, progress

47 literature underscores the utility of (18)F-FDG PET for diagnostic evaluation of parkinsonism and th

48 Performing (18)F-FDG PET for early evaluation of response often results i

49 d improve upon the current standard of (18)F-FDG PET for MYC-overexpressing TNBC.

50 aphy (PET) has added value over static (18)F-FDG PET for tumor delineation in non-small cell lung can

51 (18)F-FDG PET has previously been proven effective as an early

52 (18)F-FDG PET identified intense inter-scapular BAT glucose up

53 activity distribution patterns and the (18)F-FDG PET images from 54 patients with breast cancer were

54 FLAB-based segmentation on static (18)F-FDG PET images is in best agreement with pathology volum

55 When evaluating (18)F-FDG PET images with the Deauville score (DS), the quanti

56 (18)F-FDG PET images, postgadolinium MR images, and ADC MR ima

57 plored for biomarker development, with (18)F-FDG PET imaging being the most studied.

58 ssessed by (99m)Tc-duramycin SPECT and (18)F-FDG PET imaging in treatment-sensitive COLO205 and treat

59 (18)F-FDG PET imaging is routinely used to investigate brown a

60 At present, (18)F-FDG PET imaging is the most widely used clinical tool fo

61 estigate glucose utilization of BAT by (18)F-FDG PET imaging.

62 sed on early evaluation of response by (18)F-FDG PET in patients in the Dutch GIST registry treated w

63 dard for assessment of the accuracy of (18)F-FDG PET in predicting a response during systemic treatme

64 asibility of quantitative small-animal (18)F-FDG PET in rats by performing it repeatedly to monitor t

65 In general, (18)F-FDG PET is not useful for initial staging and is of limi

66 (18)F-FDG PET is well established in the field of oncology for

67 essed by serial CT tumor volumetry and (18)F-FDG PET metabolic volume.

68 (18)F-FDG PET often exhibits nonspecific internalization and l

69 aneoplastic syndrome and who underwent (18)F-FDG PET or (18)F-FDG PET/CT examinations met our inclusi

70 aneoplastic syndrome and who underwent (18)F-FDG PET or (18)F-FDG PET/CT examinations met our inclusi

71 e diagnostic performance of whole-body (18)F-FDG PET or (18)F-FDG PET/CT for detection of underlying

72 cificity, and diagnostic odds ratio of (18)F-FDG PET or (18)F-FDG PET/CT for the detection of underly

73 e studies demonstrates that whole-body (18)F-FDG PET or (18)F-FDG PET/CT has high diagnostic accuracy

74 d studies reporting the performance of (18)F-FDG PET or (18)F-FDG PET/CT in patients with suspected p

75 d studies reporting the performance of (18)F-FDG PET or (18)F-FDG PET/CT in patients with suspected p

76 jective and quantitative assessment of (18)F-FDG PET provides statistical incremental value for predi

77 is article reviews the data evaluating (18)F-FDG PET quantification approaches in lung diseases, focu

78 the reproducibility of their impact on (18)F-FDG PET quantification in patients with non-small cell l

79 We confirmed that (18)F-FDG PET scanning is a reliable tool for BMI assessment i

80 g cancer patients underwent diagnostic (18)F-FDG PET scans and were tested for genetic mutations.

81 (18)F-FDG PET scans were acquired in 8 healthy macaques and 8

82 Seventy (18)F-FDG PET scans were obtained for 63 GIST patients to eval

83 In addition, the (18)F-FDG PET scans were visually assessed to determine whethe

84 ntrary to findings in the human brain, (18)F-FDG PET shows cerebral hypermetabolism of aged wild-type

85 Next, we discuss how (18)F-FDG PET studies have advanced understanding of the relat

86 In addition, the value of (18)F-FDG PET studies in differential diagnosis, identifying p

87 This review focuses on recent human (18)F-FDG PET studies in Parkinson disease.

88 We performed longitudinal (18)F-FDG PET studies on 9 different PDX groups obtained by im

89 d to simulate clinical and preclinical (18)F-FDG PET time-activity curves using population-based arte

90 discordance affects the capability of (18)F-FDG PET to stratify lymphoma patients.

91 a compared favorably with the clinical (18)F-FDG PET tracer.

92 Dynamic (18)F-FDG PET using a dedicated small animal PET system was pe

93 of this study was to describe baseline (18)F-FDG PET voxel characteristics in pediatric diffuse intri

94 atment metabolic tumor volume (MTV) on (18)F-FDG PET was found to be a poor prognostic factor for pat

95 PET/MR scanner, the VOIs from DWI and (18)F-FDG PET were both within the target volume for radiother

96 of a previously acquired training set, (18)F-FDG PET with advanced discriminant analysis methods is a

97 ative brain metabolism using pediatric (18)F-FDG PET with CT data of normal pediatric brains, account

98 lytic flux seen in inflammatory cells ((18)F-FDG PET).

99 de radiomic methods using CT, MRI, and (18)F-FDG PET, as well as new radiolabeled small molecules, an

100 astine-dacarbazine (ABVD) courses with (18)F-FDG PET, enrolled in 2 international studies aimed at as

101 ompared with positive end-of-treatment (18)F-FDG PET, negative scans, indicating a CMR, were predicti

102 mprove the accuracy and consistency of (18)F-FDG PET, particularly for the assessment of tumor respon

103 with occipital lobe hypometabolism on (18)F-FDG PET, whereas relative sparing of posterior cingulate

104 he association and predictive power of (18)F-FDG PET-based radiomic features for somatic mutations in

105 A total of 13 articles (11 studies for (18)F-FDG PET-CT and 2 for LS), met the inclusion criteria.

106 Both (18)F-FDG PET-CT and LS yield high sensitivity, specificity, a

107 ED infection, based on robust data for (18)F-FDG PET-CT but limited data for LS.

108 The pooled sensitivity of (18)F-FDG PET-CT for the diagnosis of CIED infection was 87% (

109 When available,(18)F-FDG PET-CT may be preferred.

110 tologic type and clinical T stage, the (18)F-FDG PET-derived textural feature long run low gray level

111 and 13 probable DLB subjects underwent (18)F-FDG PET.

112 t of tumor heterogeneity using dynamic (18)F-FDG PET.

113 t metric for tumor quantification with (18)F-FDG PET.

114 rresponding SUVmax measured in routine (18)F-FDG PET.

115 oscopy of hyperpolarized pyruvate, and (18)F-FDG PET/computed tomographic (CT) imaging were performed

116 ve observational study, 1-hour dynamic (18)F-FDG PET/computed tomographic examinations were performed

117 mous cell carcinoma (HNSCC) by upfront (18)F-FDG PET/CT (i.e., on the day of biopsy and before the bi

118 ode (LN) staging is often performed by (18)F-FDG PET/CT (LC and MM), (68)Ga-DOTATOC PET/CT (GEP NET),

119 Conclusion:(18)F-FDG PET/CT after 1 treatment cycle is predictive of outc

120 discordant metabolic activity by both (18)F-FDG PET/CT and (11)C-MET PET/CT were Waldeyer's ring, pa

121 (18)F-FDG PET/CT and contrast-enhanced CT scans were acquired

122 Clinical data and results of (18)F-FDG PET/CT and other imaging techniques, including echoc

123 nts underwent systematic posttreatment (18)F-FDG PET/CT and were followed with at least a clinical ex

124 Clinical data and results from (18)F-FDG PET/CT at diagnosis and during follow-up were collec

125 (18)F-FDG PET/CT can be considered a valuable tool for the wor

126 (18)F-FDG PET/CT can be coupled with sensitive bone marrow-bas

127 (18)F-FDG PET/CT changed patient management in 14 cases (16%),

128 Conclusion:(18)F-FDG PET/CT correctly identified foci of increased uptake

129 IRT and (18)F-FDG PET/CT data from 8 healthy men subjected to water-ja

130 (18)F-FDG PET/CT detected all responders at 3 mo and reclassif

131 (18)F-FDG PET/CT detected metastatic infectious foci in 73.7%

132 Delayed (18)F-FDG PET/CT did not improve the specificity and the posit

133 The posttherapy (18)F-FDG PET/CT did not show any abnormal (18)F-FDG uptake (c

134 pazopanib in ovarian cancer even when (18)F-FDG PET/CT does not indicate a response.

135 sing the positivity rate of MRI versus (18)F-FDG PET/CT during the initial workup of 23 patients prov

136 ome and who underwent (18)F-FDG PET or (18)F-FDG PET/CT examinations met our inclusion criteria.

137 ome and who underwent (18)F-FDG PET or (18)F-FDG PET/CT examinations met our inclusion criteria.

138 Seventy-one (18)F-FDG PET/CT examinations were performed for 32 patients.

139 (18)F-FDG PET/CT examinations were reviewed, and the DMR was r

140 The (68)Ga-DOTATATE and (18)F-FDG PET/CT findings were discordant in 65 patients (62.5

141 ), had normal MRI results and abnormal (18)F-FDG PET/CT findings whereas the other subsets demonstrat

142 5.2% and 77.8% on standard and delayed (18)F-FDG PET/CT for an SUVmax cutoff of greater than 1.32 and

143 Individuals who underwent (18)F-FDG PET/CT for clinical indications but who did not have

144 , we recruited all those who underwent (18)F-FDG PET/CT for clinical reasons at our institution befor

145 Fourteen patients underwent (18)F-FDG PET/CT for comparison with (18)F-fluciclovine.

146 diagnostic specificity and accuracy of (18)F-FDG PET/CT for detecting cancer in patients with NSSC.

147 ormance of whole-body (18)F-FDG PET or (18)F-FDG PET/CT for detection of underlying malignancy in pat

148 ur results highlight the high yield of (18)F-FDG PET/CT for initial breast cancer staging, even in st

149 gnostic odds ratio of (18)F-FDG PET or (18)F-FDG PET/CT for the detection of underlying malignancy we

150 purpose of this study was to evaluate (18)F-FDG PET/CT for the diagnosis, management, and treatment

151 We investigated the accuracy of 3-mo (18)F-FDG PET/CT for the identification of HL patients respond

152 osis in the CT group compared with the (18)F-FDG PET/CT group (11.6 vs. 5.7 d; P = 0.02).

153 (18)F-FDG PET/CT had no clinical impact on G1 NETs and a moder

154 (18)F-FDG PET/CT has become the reference standard in oncologi

155 rates that whole-body (18)F-FDG PET or (18)F-FDG PET/CT has high diagnostic accuracy and moderate to

156 The predominant finding on brain (18)F-FDG PET/CT imaging was lobar hypometabolism, being obser

157 nd 5 and 10 wk after start of therapy) (18)F-FDG PET/CT imaging was performed in patients with newly

158 bserved with the control group or with (18)F-FDG PET/CT imaging.

159 hologic complete response is SUVmax in (18)F-FDG PET/CT imaging.

160 stant metastasis rate (DMR) on initial (18)F-FDG PET/CT in a group of breast cancer patients younger

161 e investigated the diagnostic value of (18)F-FDG PET/CT in chronic Q fever at diagnosis and during fo

162 his study, we investigated the role of (18)F-FDG PET/CT in patients with SAB for detection of metasta

163 ng the performance of (18)F-FDG PET or (18)F-FDG PET/CT in patients with suspected paraneoplastic syn

164 ng the performance of (18)F-FDG PET or (18)F-FDG PET/CT in patients with suspected paraneoplastic syn

165 dy of all adult patients who underwent (18)F-FDG PET/CT in search of a focal source of infection was

166 to assess the value of dual-timepoint (18)F-FDG PET/CT in the prediction of lymph node (LN) status i

167 All patients underwent two (18)F-FDG PET/CT investigations on two different days (time di

168 Conclusion:(18)F-FDG PET/CT is a valuable technique for early detection o

169 Conclusion:(18)F-FDG PET/CT is a valuable technique in diagnosis of chron

170 Standard (18)F-FDG PET/CT is an effective preoperative imaging method f

171 Performing (18)F-FDG PET/CT is associated with significantly reduced 3-mo

172 (18)F-FDG PET/CT is feasible for noninvasive monitoring of tre

173 The use of (18)F-FDG PET/CT is mandatory to confirm a suspected diagnosis

174 (18)F-FDG PET/CT is often used for restaging after NAC and to

175 (18)F-FDG PET/CT is potentially applicable to predict response

176 (18)F-FDG PET/CT led to a total of 104 treatment modifications

177 Thus, (18)F-FDG PET/CT may play a significant role during posttreatm

178 Brain (18)F-FDG PET/CT may play a significant role in the initial ev

179 tion parameters used in their clinical (18)F-FDG PET/CT oncology protocols.

180 ents were randomized 1:1 to whole-body (18)F-FDG PET/CT or CT of the thorax and abdomen as the imagin

181 t impact on the diagnostic accuracy of (18)F-FDG PET/CT performed for evaluation of known or suspecte

182 hod for early response evaluation with (18)F-FDG PET/CT performed most optimally for the prediction o

183 high-risk bacteremia patients without (18)F-FDG PET/CT performed than in those in whom (18)F-FDG PET

184 owever, in poorly differentiated NETs, (18)F-FDG PET/CT plays a significant clinical role in combinat

185 (18)F-FDG PET/CT plays a significant role in the assessment of

186 l study aimed to verify whether serial (18)F-FDG PET/CT predicts doxorubicin cardiotoxicity.

187 tection rate of (18)F-FDG PET/MRI than (18)F-FDG PET/CT regarding small lung nodules should be consid

188 2007 to January 2015 identified 2,588 (18)F-FDG PET/CT reports referring to the thyroid.

189 Conclusion:(18)F-FDG PET/CT results may act as a biomarker for the presen

190 hy, white blood cell scintigraphy, and (18)F-FDG PET/CT results.

191 ts underwent a preoperative whole-body (18)F-FDG PET/CT scan at 1 h (standard examination) and an add

192 tients (n = 133) underwent an adequate (18)F-FDG PET/CT scan before surgery between January 2003 and

193 locally advanced EC and a pretreatment (18)F-FDG PET/CT scan between 2009 and 2015.

194 locally advanced EC and a pretreatment (18)F-FDG PET/CT scan between 2009 and 2015.

195 ed until March 2015, when at least one (18)F-FDG PET/CT scan was obtained.

196 Three-month (18)F-FDG PET/CT scans detected HL patients responding to anti

197 We analyzed 2,854 (18)F-FDG PET/CT scans from 1,644 patients and identified 98 s

198 At diagnosis, 19.6% of (18)F-FDG PET/CT scans led to treatment modification.

199 (18)F-FDG PET/CT scans of 14 patients with metal implants (eit

200 rvices coverage includes 3 posttherapy (18)F-FDG PET/CT scans per patient and per tumor type.

201 Of all (18)F-FDG PET/CT scans performed at diagnosis, 13.5% led to a

202 erall, fourth and subsequent follow-up (18)F-FDG PET/CT scans resulted in change in management in 31.

203 During follow-up, 57.3% of (18)F-FDG PET/CT scans resulted in treatment modification.

204 rming a fourth or additional follow-up (18)F-FDG PET/CT scans that could affect the management of pat

205 Methods:(18)F-FDG PET/CT scans were obtained before and after 7-10 d o

206 (18)F-FDG PET/CT scans were prospectively reevaluated by 3 nuc

207 Any additional follow-up (18)F-FDG PET/CT scans will be reimbursed at the discretion of

208 e (HD) and had undergone 4 consecutive (18)F-FDG PET/CT scans.

209 (18)F-FDG PET/CT should therefore be considered as first-line

210 Mice imaged with (18)F-FDG PET/CT showed cerulein-enhanced pancreatic uptake in

211 Conclusion:(18)F-FDG PET/CT shows good accuracy in posttreatment evaluati

212 All had paired (11)C-MET PET/CT and (18)F-FDG PET/CT studies at diagnosis.

213 We compared 50 (18)F-FDG PET/CT studies collected prospectively from 14 patie

214 Methods: We compared 50 (18)F-FDG PET/CT studies collected prospectively from 14 patie

215 he final study population included 176 (18)F-FDG PET/CT studies in 153 patients (107 men, 46 women; a

216 (18)F-FDG PET/CT studies were analyzed both qualitatively and

217 DOPA PET/CT studies, and 176 MBq in 13 (18)F-FDG PET/CT studies.

218 tive (29%) and 17 false-positive (10%) (18)F-FDG PET/CT studies.

219 started before the performance of the (18)F-FDG PET/CT study.

220 The sensitivity of (18)F-FDG PET/CT to detect residual tumor tissue was 92% (95%

221 Based on the ability of (18)F-FDG PET/CT to distinguish between metabolically active a

222 CT + head and neck MRI (CHCT/MRI) with (18)F-FDG PET/CT upfront in the diagnostic workup of patients

223 cephalitides, comparing the utility of (18)F-FDG PET/CT versus conventional brain imaging with MRI.

224 nd without vascular infection based on (18)F-FDG PET/CT was 23.8% and 2.1%, respectively (P = 0.001).

225 (18)F-FDG PET/CT was able to reclassify 63 of 70 (90%) patient

226 When (18)F-FDG PET/CT was added as a major criterion to the modifie

227 In a subgroup analysis, (18)F-FDG PET/CT was found to have a significantly higher spec

228 Overall, (18)F-FDG PET/CT was more often abnormal during the diagnostic

229 PET/CT performed than in those in whom (18)F-FDG PET/CT was performed (32.7% vs. 12.4%, P = 0.003).

230 (18)F-FDG PET/CT was performed 1-8 mo (median, 4 mo) after com

231 ients with advanced nonsquamous NSCLC, (18)F-FDG PET/CT was performed before treatment and after 2 wk

232 tal of 184 patients were included, and (18)F-FDG PET/CT was performed in 105 patients, of whom 99 had

233 atic complications were present before (18)F-FDG PET/CT was performed.

234 f the study was to investigate whether (18)F-FDG PET/CT was superior to CT as an initial imaging moda

235 In multivariate analysis, (18)F-FDG PET/CT was the only factor independently associated

236 lue, and negative predictive value for (18)F-FDG PET/CT were 82%, 96%, 94%, and 87%, respectively.

237 abolic tumor volume (TMTV) measured on (18)F-FDG PET/CT with adaptive thresholding methods with TMTV

238 nical examination, and who had initial (18)F-FDG PET/CT within 3 mo after pathologic breast cancer di

239 ewly diagnosed metastatic infection by (18)F-FDG PET/CT, subsequent treatment modifications, and pati

240 this, the performance of posttreatment (18)F-FDG PET/CT, the impact on patient care, and the predicti

241 one side and a comprehensive range of (18)F-FDG PET/CT-derived parameters on the other side in chemo

242 The following (18)F-FDG PET/CT-derived parameters were computed: maximum dia

243 he associations among CTCs, cfDNA, and (18)F-FDG PET/CT-derived parameters were evaluated by multivar

244 n pretreatment clinical parameters and (18)F-FDG PET/CT-derived textural features.

245 bility rate of infectious processes by (18)F-FDG PET/CT.

246 mide ((125)I-iodo-DPA-713) SPECT/CT or (18)F-FDG PET/CT.

247 Ts) underwent both (68)Ga-DOTATATE and (18)F-FDG PET/CT.

248 ution of (11)C-MET PET/CT with that of (18)F-FDG PET/CT.

249 underwent complete staging, including (18)F-FDG PET/CT.

250 tion was minimal in non-time-of-flight (18)F-FDG PET/MR brain imaging.

251 (18)F-FDG PET/MR images of mouse and rat brains showed no sign

252 nts, a clinically indicated whole-body (18)F-FDG PET/MR scan was acquired.

253 technique was assessed in simultaneous (18)F-FDG PET/MR scans of a canine model of myocardial infarct

254 In the case of (18)F-FDG PET/MRI (C), RDs for the whole brain were -11%, -8%,

255 In this report, the feasibility of an (18)F-FDG PET/MRI approach for improved diagnosis of chronic s

256 lic cage, infrared thermal imaging and (18)F-FDG PET/MRI experiments.

257 The feasibility of (18)F-FDG PET/MRI for diagnosing pain generators in chronic sc

258 A reduction of doses in (18)F-FDG PET/MRI might be possible down to 2 MBq/kgBW in onco

259 Whole-body (18)F-FDG PET/MRI scans were obtained for 12 patients after PE

260 The lower detection rate of (18)F-FDG PET/MRI than (18)F-FDG PET/CT regarding small lung n

261 Methods:(18)F-FDG PET/MRI was performed on 9 chronic sciatica patients

262 ough most small lung nodules missed on (18)F-FDG PET/MRI were found to be benign, there was a relevan

263 )F-FDG PET combined with MRI (combined (18)F-FDG PET/MRI) in patients with suspected spondylodiskitis

264 nd on oncologic readings in whole-body (18)F-FDG PET/MRI.

265 (18)F-fluorodeoxyglucose ((18)F-FDG) PET/CT has demonstrated value for SPNs diagnosis wi

266 optimal use of (18)fluorodeoxyglucose ((18)F-FDG) PET/CT in patients with multiple myeloma and other

267 -DOTATATE PET imaging was compared to [(18)F]FDG PET imaging in 42 patients with atherosclerosis.

268 glucose positron emission tomography ([(18)F]FDG PET), [(18)F]FDG lacks cell specificity, and coronar

269 ion by routine metabolic imaging with [(18)F]FDG-PET failed due to low standard uptake values and low

270 ant and inflamed lymph nodes, whereas [(18)F]FDG-PET failed to do so.

271 gnosing DLBCL in the clinic; however, [(18)F]FDG-PET often faces difficulty in differentiating malign

272 glucose positron emission tomography ([(18)F]FDG-PET) imaging has an essential role in diagnosing DLB

273 model and to determine the value of [(18)F]-FDG-PET/CT as a biomarker for disease and treatment outc

274 ional studies to demonstrate whether [(18)F]-FDG-PET/CT can identify other, subtler effects.

275 Quantitative analysis of [(18)F]-FDG-PET/CT images revealed differences between moribund

276 [(18)F]-FDG-PET/CT imaging can provide real-time snapshots of me

277 s involved in the immune response by [(18)F]-FDG-PET/CT imaging is a powerful tool for identifying ke

278 In this study, we investigated [(18)F]-FDG-PET/CT imaging of immune processes in lymphoid tissu

279 t of 329 individuals had fluorodeoxyglucose (FDG) PET.

280 went DCE-MRI, and a subgroup of patients had FDG-PET.

281 tion is, therefore, needed when interpreting FDG PET/CT in suspected prosthetic valve endocarditis, w

282 MSOT was compared with intravenous FDG PET/CT.

283 iation to the FDG-avid tumor on midtreatment FDG-PET to improve local tumor control of locally advanc

284 o the residual tumor defined on midtreatment FDG-PET up to a total dose of 86 Gy in 30 daily fraction

285 exploratory analyses, diagnostic accuracy of FDG-PET/CT was better than ceCT alone or ceCT combined w

286 MM patients with simultaneous assessment of FDG-PET and DWIBS, and to identify tumor-intrinsic featu

287 e was the negative predictive value (NPV) of FDG-PET/CT scans and other supporting diagnostic test ch

288 performed a prospective multicenter study of FDG-PET/CT scanning 12 weeks after CCRT in newly diagnos

289 IBS may be reported as being disease-free on FDG-PET ("PET false-negative").

290 d from various texture features on dual time FDG PET/CT images (DTPI) can differentiate between malig

291 ron emission tomography/computed tomography (FDG-PET/CT) acquired during the course of treatment prov

292 ron emission tomography/computed tomography (FDG-PET/CT) scan of the neck in locoregionally advanced

293 rodeoxyglucose-positron emission tomography (FDG-PET) has become a central tool for both accurate ini

294 rodeoxyglucose positron emission tomography (FDG-PET) imaging to determine the utility of response-ad

295 rodeoxyglucose positron emission tomography (FDG-PET) imaging to understand the neural systems govern

296 ordeoxyglucose positron emission tomography (FDG-PET).

297 Fludeoxyglucose Positron Emission Tomography(FDG-PET).

298 shape, texture) extracted from pre-treatment FDG-PET and CT images of 300 patients from four differen

299 n and temozolomide therapy and who underwent FDG PET/computed tomography because of radiologic deteri

300 monstrate a relevant number of patients with FDG-PET false-negative MM and a strong association betwe